Researchers at the Hassadah Medical Center in Jerusalem will conduct a Phase II clinical trial to assess the impact of CBD as single treatment in cancer patients who have failed to respond to conventional therapies. Participants in the trial will receive CBD therapy for a period of eight weeks.
Ample data exists documenting the potent anti-cancer activity of various cannabinoids – including THC, CBD, and CBG – both in culture and in animal models. However, virtually no clinical trials exist reproducing these results in human subjects.
In August, pharmaceutical provider Insys Therapeutics announced that it had received orphan drug status for its proprietary formulation of CBD for the treatment of glioblastoma, a hard-to-treat aggressive form of brain cancer.
Organic CBD is classified under federal law as a schedule I controlled substance.
For more information, please contact Paul Armentano, NORML Deputy Director, at: email@example.com.